Reviewing ARS Pharmaceuticals (NASDAQ:SPRY) & Sunshine Biopharma (NASDAQ:SBFM)

Sunshine Biopharma (NASDAQ:SBFM) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Valuation and Earnings

This table compares Sunshine Biopharma and ARS Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	0.05	-$5.97 million	($10.15)	-0.04
ARS Pharmaceuticals	$84.28 million	5.06	-$171.30 million	($2.18)	-1.97

Sunshine Biopharma has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sunshine Biopharma has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 1.7% of Sunshine Biopharma shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sunshine Biopharma and ARS Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	1	0	2.00
ARS Pharmaceuticals	1	1	4	0	2.50

Sunshine Biopharma currently has a consensus target price of $70.00, suggesting a potential upside of 16,562.70%. ARS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 482.75%. Given Sunshine Biopharma’s higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than ARS Pharmaceuticals.

Profitability

This table compares Sunshine Biopharma and ARS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.